Senile deafness and metabolic bone disease.
In 56 patients with senile deafness, the degree of bone atrophy was quantitatively assessed by microdensitometry (MD). Biochemical examinations were also made. The following results were obtained: 1. Abnormal bone metabolism is suspected in many patients with senile deafness. 2. Serum calcium level is significantly lower and BUN significantly higher in patients with senile deafness than in normal subjects. 3. A significant positive correlation is noted between hearing levels and serum alkaline phosphatase levels in patients with senile deafness. After treatment of 12 patients suspected of having abnormal bone metabolism (as judged by MD) with an active vitamin D preparation (1 alpha-[OH]D3) at 1 microgram/day for 6 to 10 months, hearing improvement was noted for six ears (four patients). However, long-term observation is necessary to be able to assess the efficacy of active vitamin D on senile deafness, which is a result of chronic aggravation of hearing impairment.
Yamazaki
T
T
Department of Neurotology, Sapporo City General Hospital, Japan.
Ogawa
K
K
Imoto
T
T
Hayashi
N
N
Kozaki
H
H
D000328:Adult; D000368:Aged; D000375:Aging / Q000378:metabolism* / Q000502:physiology; D001284:Atrophy / Q000150:complications; D001851:Bone Diseases, Metabolic / Q000150:complications*; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology; D003638:Deafness / Q000188:drug therapy / Q000209:etiology*; D003720:Densitometry; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
D006887:Hydroxycholecalciferols; C008088:alfacalcidol